In this segment, panelists discuss the phase III MA.31 trial that examined lapatinib or trastuzumab with a taxane-based chemotherapy to treat patients with HER2-positive metastatic breast cancer. To view more from this discussion, visit http://www.onclive.com/peer-exchange/...